• Corpus ID: 1585720

Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.

  title={Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.},
  author={N. Yoshimura and Eiji Mizuta and Osamu Yoshida and Sadako Kuno},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={286 1},
  • N. Yoshimura, E. Mizuta, S. Kuno
  • Published 1 July 1998
  • Biology, Medicine, Psychology
  • The Journal of pharmacology and experimental therapeutics
The effects of dopamine receptor agonists on urinary bladder function were evaluated in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys to investigate the therapeutic efficacy in the treatment of urinary symptoms in Parkinson's disease. Under ketamine anesthesia, cystometrograms exhibited significant reduction in the volume threshold for the micturition reflex in MPTP-lesioned parkinsonian monkeys when compared with those of normal monkeys… 

Figures from this paper

Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats
The results suggest that in conscious rats, D1 receptors tonically inhibit the micturition reflex and that D2 receptors are involved in facilitation of the mitzurition Reflex, which may be speculated that detrusor hyperreflexia associated with Parkinson's disease results from activation failure of D 1 receptors and that administration of D2 receptor agonists might worsen the condition.
GABAergic mechanism mediated via D1 receptors in the rat periaqueductal gray participates in the micturition reflex: an in vivo microdialysis study
The present study elucidated dynamic changes in dopamine, glutamate and γ‐aminobutyric acid in the rat PAG during the micturition reflex, with a focus on dopaminergic modulation using in vivo microdialysis combined with cystometrography.
Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation.
Tamadol effectively suppresses apomorphine induced detrusor overactivity in doses shown to have analgesic activity and may provide an approach to treat lower urinary tract disorders in which dopamine receptor activation is involved.
Neuronal excitation in the ventral tegmental area modulates the micturition reflex mediated via the dopamine D1 and D2 receptors in rats.
The results suggested that the facilitated micturition reflex might be mediated via the dopamine D(2) receptors, while the inhibitory effects on the mictURition reflex was mediated through the dopamineD(1) receptors.
Altered detrusor contractility in MPTP-treated common marmosets with bladder hyperreflexia
The present data indicates that the increased neurogenically mediated contractions where no extrinsic innervation exists might be due to long-term adaptive changes locally as a result of the loss of the nigrostriatal output.
The role of 5-hydrooxytryptamine receptors in the control of micturition.
  • R. Ke
  • Biology, Medicine
  • 2004
The data demonstrate that facilitation of micturition was possible using 5-CT, but only in the presence of the selective 5 -H T ib/id receptor antagonist GR127935, and further characterises the functional role of 5-HT receptors in the control of mitzurition.
Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6‐hydroxydopamine (6‐OHDA) lesion of the nigrostriatal pathway
The results indicate that a rat model of PD exhibited bladderhyperactivity as observed in patients with PD, and that stimulation of D1/D5 dopamine receptors at a supraspinal site can suppress bladder hyperactivity in PD, whereas stimulation ofD2/D4, but not D3, dopamine receptors had the opposite effect to reduce bladder capacity.


Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
It is suggested that stimulation of either central dopamine D1 or D2 receptors is requisite for the antiparkinsonian effects and concurrent strong stimulation of both central Parkinson's disease receptors causes marked hyperactivity which may be predictive of dopaminergic psychiatric side effects.
Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
Combination therapy with a partial D2 agonist and a full D1 agonist or monotherapy with a dopamine agonist that has both partial D 2 and full D 1 agonist properties might be beneficial for treating motor dysfunction in Parkinson's disease without inducing dopaminergic side effects.
The Response of Subthalamic Nucleus Neurons to Dopamine Receptor Stimulation in a Rodent Model of Parkinson’s Disease
The premise that therapeutic efficacy in the treatment of Parkinson’s disease is associated with a decrease in the activity of the STN is supported, but assumptions about the roles of D1 and D2 receptors in the regulation of neuronal activity ofThe STN in both the intact and dopamine-depleted states are challenged.
The rationale for the use of dopamine agonists in Parkinson's disease
The production of dyskinesias in Parkinson's disease might reflect an imbalance in the D1-direct and D2-indirect GABAergic output pathways from the caudate-putamen, which colocalize tachykinins and enkephalins, respectively, and levodopa treatment leads to a new imbalance between output from the striatum through the direct and indirect pathways.
D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors.
D1 agonism is capable of augmenting and altering dopaminergic behavior of both mixed D1/D2 and D2 dopamine receptor agonists and may represent optimal drug treatment for Parkinson's disease.
Dopamine D-1 receptors in the parkinsonian brain
Dopamine D‐1 receptor‐mediated inhibition of micturition reflex by central dopamine from the substantia nigra
It is suggested that central dopamine derived from the pars compacta of the SN inhibits the micturition reflex via dopamine D‐1 receptors probably in the afferent pathway form the sacral spinal cord to the locus coeruleus, although the possibility that it acts on the efferent pathways originating in areas other than locus coercedus could not completely be excluded.
Dopamine receptor pharmacology.